Drug Trial Radar · NCT05144256
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Jun 8, 2022
Primary completion
May 3, 2024
Study completion Jun 2029
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participants will be randomized 2:1 to receive either mitapivat or matching placebo. Randomization will be stratified by age (1 to \< 6 years, 6 to \< 12 years, 12 to \< 18 years) and splenectomy status. Participants will be dosed by age and weight during a double-blind period consisting of an 8-week dose titration period followed by a 24-week fixed-dose period. Participants who complete the double-blind period will be eligible to receive mitapivat in the open-label extension (OLE) period.
Conditions
- Pediatric Pyruvate Kinase Deficiency
- Pediatric Hemolytic Anemia
Interventions
MitapivatDrug
Tablets or granules
Mitapivat-matching placeboDrug
Tablets or granules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Transfusion Reduction Response (TRR)Time frame: Week 9 to Week 32
Locations
22 sites in 10 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Stanford Medicine
Palo Alto, California
Children's Healthcare of Atlanta - Emory
Atlanta, Georgia
Boston Children's Hospital
Boston, Massachusetts
Cure 4 the Kids Foundation, A Division of Roseman University of Health Sciences
Las Vegas, Nevada
Weill Cornell Medical College
New York, New York
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UT Southwestern Medical Center
Dallas, Texas
Texas Children's Hospital
Houston, Texas
Comprehensive Hemophilia Care Clinic at CHEO (Children's Hospital Eastern Ontario)
Ottawa, Ontario, Canada
Fakultní Nemocnice Olomouc
Olomouc, Czechia
Rigshospitalet
Copenhagen, Denmark
Aarhus University Hospital
Aarhus, Central Jutland, Denmark
Charite - UB - CVK - Medizinische Klinik
Berlin, Germany
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Clinico Universitario Virgen de la Arrixaca
Madrid, Spain
CHUV University Hospital of Lausanne
Lausanne, Canton of Bern, Switzerland
Hacettepe University
Ankara, Turkey (Türkiye)
İstanbul Üniversitesi Tıp Fakültesi [Istanbul University Faculty of Medicine] Çocuk Sağlığı Enstitüsü [Institute of Child Health]
Istanbul, Turkey (Türkiye)
Ege University Faculty of Medicine
Izmir, Adana, Turkey (Türkiye)
King's College Hospital NHS
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.